The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Nektar Therapeutics (NASDAQ: NKTR) who purchased shares between November 11, 2017 and October 2, 2018. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.
(1) prior studies which attempted to pegylate IL-2 failed; (2) the extended half-life of the Company’s lead I-O candidate, NKTR-214, was unlikely to result in efficacy and created additional high-dosing safety concerns; (3) NKTR-214 was less effective than IL-2 alone; (4) the combination of NKTR-214 with nivolumab has yet to demonstrate significant positive results; and (5) as a result, Nektar’s public statements as set forth above were materially false and misleading at all relevant times.
Shareholders have until December 31, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >